Replies to post #240867 on Biotech Values

[DewDiligence]

Maybe. But Antios' ATI-2173 is a tweaked version of Clevudine, a drug that Pharmasset discontinued 12.5 years ago (#msg-37166326, #msg-37153049).

[DewDiligence]

ABUS 2022 news flow:

https://www.globenewswire.com/news-release/2022/01/24/2371584/14025/en/Arbutus-Announces-2022-Corporate-Objectives-and-Provides-Financial-Update.html

[DewDiligence]

ASMB dumps Antios HBV collaboration_following safety problem:

https://www.sec.gov/ix?doc=/Archives/edgar/data/1426800/000156459022021134/asmb-8k_20220518.htm

On May 18, 2022, Assembly Biosciences, Inc. (the “Company”) was notified by Antios Therapeutics, Inc. (“Antios”) that ATI-2173, Antios’s investigational proprietary active site polymerase inhibitor nucleotide, has been placed on clinical hold by the U.S. Food and Drug Administration following submission of a safety report involving a patient who received a triple combination of the Company’s lead core inhibitor, vebicorvir, ATI-2173 and a nucleos(t)ide analog reverse transcriptase inhibitor.

Effective May 20, 2022, because of the clinical hold, the Company terminated the Clinical Trial Collaboration Agreement between the Company and Antios.

I didn’t think much of ATI-2173 anyhow—see #msg-164648753 and #msg-167129703.